Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.31 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL765779 | 1.00 | TSHR (0.47) | TSHRTDP1ALDH1A1MAPK1ANPEP | |
| SCHEMBL17365007 | 1.00 | TSHR (0.47) | TSHRTDP1ALDH1A1MAPK1ANPEP | |
| SCHEMBL4610047 | 0.87 | TSHR (0.44) | TSHRTDP1 | |
| SCHEMBL13143420 | 0.84 | TSHR (0.50) | TSHRTDP1ALDH1A1MAPK1ANPEP | |
| SCHEMBL1613823 | 0.80 | TSHR (0.40) | TSHRTDP1 | |
| SCHEMBL9989406 | 0.79 | TSHR (0.41) | TSHRTDP1ALDH1A1MAPK1ANPEP | |
| SCHEMBL571433 | 0.79 | — | — | |
| SCHEMBL7249315 | 0.79 | TSHR (0.44) | TSHRTDP1ALDH1A1MAPK1ANPEP | |
| SCHEMBL4611087 | 0.79 | TSHR (0.39) | TSHRTDP1 | |
| SCHEMBL1614947 | 0.79 | TSHR (0.44) | TSHRTDP1ALDH1A1MAPK1ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118234830-A | Selective wet etching composition and method | 恩特格里斯公司 | 2024-06-21 | — | — | CN | disclosed |
| US-20240198157-A1 | PREPARATION OF A FOAM STABILIZING COMPOSITION INCLUDING A SILOXANE CATIONIC SURFACTANT AND A METAL SALT | DOW SILICONES CORP (US) | 2024-06-20 | — | — | US | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-11795159-B2 | Compounds for the treatment of SARS | PURDUE RESEARCH FOUNDATION (US) | 2023-10-24 | — | — | US | disclosed |
| US-RE49687-E1 | Thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230270751-A1 | BENZODIAZEPINE DERIVATIVES USEFUL IN TREATING A RESPIRATORY SYNCYTIAL VIRUS INFECTION | PFIZER INC. | 2023-08-31 | — | — | US | disclosed |
| US-11708446-B2 | Polymers and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-07-25 | — | — | US | disclosed |
| US-11679292-B2 | Cationic surfactant foam stabilizing composition | DOW SILICONES CORPORATION (US) | 2023-06-20 | — | — | US | disclosed |
| US-10202379-B2 | Substituted polycyclic carbamoyl pyridone derivative prodrug | SHIONOGI & CO., LTD. (JP) | 2019-02-12 | — | — | US | disclosed |
| US-20180208699-A1 | POLYMERS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2018-07-26 | — | — | US | disclosed |
| US-20110218194-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | Schering Corporation & Pharmacopeia Drug Discovery Inc. (US) | 2011-09-08 | — | — | US | disclosed |
| US-20110105463-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2011-05-05 | — | — | US | disclosed |
| US-7700603-B2 | Heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| US-7459460-B2 | Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459460-B2 | Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-02 | — | — | US | disclosed |
| EP-1713749-B1 | METHOD FOR THE PRODUCTION OF OLEFINS COMPRISING 8 TO 12 CARBON ATOMS | EVONIK OXENO GMBH (DE) | 2008-07-23 | — | — | EP | disclosed |
| US-20070135665-A1 | Method for the production of olefins comprising 8 to 12 carbon atoms | EVONIK OXENO GMBH (DE) | 2007-06-14 | — | — | US | disclosed |
| CN-1914138-A | Method for preparing olefin containing 8-12 carbon atoms | OXENO OLEFINCHEMIE GMBH (DE) | 2007-02-14 | — | — | CN | disclosed |
| EP-1713749-A1 | METHOD FOR THE PRODUCTION OF OLEFINS COMPRISING 8 TO 12 CARBON ATOMS | Oxeno Olefinchemie GmbH (DE) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005080302-A1 | METHOD FOR THE PRODUCTION OF OLEFINS COMPRISING 8 TO 12 CARBON ATOMS | OXENO OLEFINCHEMIE GMBH (DE) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270751-A1 | BENZODIAZEPINE DERIVATIVES USEFUL IN TREATING A RESPIRATORY SYNCYTIAL VIRUS INFECTION | CNR1, CNR2, SIGMAR1 | TSHR 80/4885TDP1 4627/4885ALDH1A1 2970/4885 |
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | TSHR 4679/4885TDP1 611/4885ALDH1A1 656/4885 |
| US-20070135665-A1 | Method for the production of olefins comprising 8 to 12 carbon atoms | ADH1A, ADH1C, HPD | TSHR 4769/4885TDP1 4010/4885ALDH1A1 24/4885 |
| US-20110218194-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, PRSS1 | TSHR 1151/4885TDP1 534/4885ALDH1A1 4505/4885 |
| US-11795159-B2 | Compounds for the treatment of SARS | ACE2, ACE, SARS1 | TSHR 4314/4885TDP1 4473/4885ALDH1A1 3093/4885 |
| US-20110105463-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | GPR52, CD22, CD4 | TSHR 500/4885TDP1 3146/4885ALDH1A1 756/4885 |
| US-10202379-B2 | Substituted polycyclic carbamoyl pyridone derivative prodrug | PREP, UNG, DPP4 | TSHR 3454/4885TDP1 293/4885ALDH1A1 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.